{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:14:48Z","timestamp":1791832488294,"version":"4.3.4"},"reference-count":69,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.1080\/21645515.2024.2409502","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T11:22:46Z","timestamp":1728559366000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Factor H binding protein (FHbp): An evaluation of genotypic diversity across\n            <i>Neisseria meningitidis<\/i>\n            serogroups"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7934-429X","authenticated-orcid":false,"given":"Zhenghui","family":"Li","sequence":"first","affiliation":[{"name":"Pfizer Inc","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlesh Krishna","family":"Murthy","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8865-7351","authenticated-orcid":false,"given":"Li","family":"Hao","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubomira","family":"Andrew","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliesa S.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"issue":"2","key":"e_1_3_5_2_1","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Cohn AC","year":"2013","unstructured":"Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR\u20132):1\u201313. https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr6202a1.htm.","journal-title":"MMWR Recomm Rep"},{"key":"e_1_3_5_3_1","volume-title":"Chapter 8: meningococcal disease. Manual for the Surveillance of Vaccine-Preventable Diseases","author":"MacNeil J","year":"2017","unstructured":"MacNeil J, Cohn A. Chapter 8: meningococcal disease. Manual for the Surveillance of Vaccine-Preventable Diseases. 5th ed. Atlanta (GA): Centers for Disease Control and Prevention; 2017.","edition":"5"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61016-2"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000606"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268823000328"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00499-3"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7954-11-17"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2020.1990"},{"key":"e_1_3_5_10_1","unstructured":"Centers for Disease Control and Prevention. Enhanced Meningococcal Disease Surveillance Report. 2016 [accessed 2024 Aug 19]. https:\/\/stacks.cdc.gov\/view\/cdc\/49452."},{"key":"e_1_3_5_11_1","unstructured":"European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases: invasive meningococcal disease. [accessed 2024 Aug 19]. https:\/\/atlas.ecdc.europa.eu\/public\/index.aspx?Dataset=27&HealthTopic=36."},{"key":"e_1_3_5_12_1","unstructured":"Public Health Agency of Canada. Vaccine preventable disease: surveillance report to December 31. 2015. [accessed 2024 Aug 19]. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/vaccine-preventable-disease-surveillance-report-december-31-2015.html."},{"key":"e_1_3_5_13_1","unstructured":"Australian Government Department of Health. Invasive meningococcal disease national surveillance report with a focus on MenW. 2017."},{"key":"e_1_3_5_14_1","unstructured":"New Zealand Ministry of Health. Notifiable diseases in New Zealand annual report 2016. [accessed 2024 Aug 19]. https:\/\/sacnzs.org.nz\/assets\/1Reports\/Public-Health-Surveillance-\/Annual-notifiable-disease-report-and-data\/esr-notifiable-diseases-annual-surveillance-summary-2016.pdf."},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2021.1940144"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90340-9"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.4.2088-2100.2004"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021911"},{"key":"e_1_3_5_19_1","volume-title":"Trumenba\u00ae (meningococcal group B vaccine)","author":"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc","year":"2021","unstructured":"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. Trumenba\u00ae (meningococcal group B vaccine). Philadelphia (PA): Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.; 2021."},{"key":"e_1_3_5_20_1","volume-title":"Bexsero (meningococcal group B vaccine [rDNA, component, adsorbed]). Summary of product characteristics","author":"GSK Vaccines Srl","year":"2022","unstructured":"GSK Vaccines Srl. Bexsero (meningococcal group B vaccine [rDNA, component, adsorbed]). Summary of product characteristics. Siena, Italy: GSK Vaccines Srl; 2022."},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07769"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.501"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1086\/597806"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.7.0.14564"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.12.022"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.05.081"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13660"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02847"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.34293"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.027995-0"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00056-12"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejm200104053441406"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.05182-11"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01071-08"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/cvi.00260-13"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003470"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31829aa63b"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1086\/600141"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00055-11"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03584-13"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.06.025"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107240"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-346-2_1"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2015.1016915"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.06.083"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1264750"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1307"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614474"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001399"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2022.2064850"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1521142113"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00036-18"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.538209"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.11.072"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.079921-0"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.25800"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2015.02.006"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2180-14-111"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.01.030"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-595"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.14826.1"},{"key":"e_1_3_5_62_1","volume-title":"Trumenba (meningococcal group B vaccine)","author":"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc","year":"2024","unstructured":"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. Trumenba (meningococcal group B vaccine). Philadelphia (PA): Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.; 2024."},{"key":"e_1_3_5_63_1","volume-title":"Trumenba (meningococcal group B vaccine). Summary of product characteristics","author":"Pfizer Europe MA EEIG","year":"2022","unstructured":"Pfizer Europe MA EEIG. Trumenba (meningococcal group B vaccine). Summary of product characteristics. Bruxelles, Belgium: Pfizer Europe MA EEIG; 2022."},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001302"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065043"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.000006-0"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-015-0469-6"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2202.150369"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu881"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.051"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2024.2409502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T17:32:08Z","timestamp":1744651928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2024.2409502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,31]]}},"alternative-id":["10.1080\/21645515.2024.2409502"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2024.2409502","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-05-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2409502"}}